Table 1. Clinicopathological features of the childhood ALL patients.
| Variables | N (%) |
|---|---|
| Gender | |
| Male | 73 (58.4) |
| Female | 52 (41.6%) |
| Age | |
| 1–9 years | 84 (67.2) |
| <1 or ⩾10 years | 41 (32.8) |
| WBC | |
| <50 000 cells per μl | 102 (81.6) |
| ⩾50 000 cells per μl | 23 (18.4) |
| Immunophenotype | |
| Precursor B-ALL | 110 (88.0) |
| CD10+ | 104 (83.2) |
| CD10− | 6 (4.8) |
| T-ALL | 15 (12.0) |
| High hyperdiploidy (>50 chromosomes) | |
| Yes | 22 (17.6) |
| No | 102 (81.6) |
| Unknown | 1 (0.8) |
| Hypodiploidy (⩽45 chomosomes) | |
| Yes | 4 (3.2) |
| No | 120 (96.0) |
| Unknown | 1 (0.8) |
| TEL-AML1/t(12;21)(p13;q22) | |
| Negative | 93 (74.4) |
| Positive | 31 (24.8) |
| Unknown | 1 (0.8) |
| Philadelphia chromosome BCR-ABL1/t(9;22)(q34;q11) | |
| Negative | 122 (97.6) |
| Positive | 2 (1.6) |
| Unknown | 1 (0.8) |
| BM on day 15 | |
| M1 (blasts <5%) | 103 (82.4) |
| M2 (blasts 5–25%) | 16 (12.8) |
| M3 (blasts >25%) | 6 (4.8) |
| MRD on day 15 | |
| <0.01% | 22 (17.6) |
| >0.01% | 67 (53.6) |
| Unknown | 36 (28.8) |
| MRD on day 33 | |
| <0.01% | 50 (40.0) |
| >0.01% | 21 (16.8) |
| Unknown | 54 (43.2) |
| Prednisone response on day 8 | |
| Good (<1000 blasts) | 112 (89.6) |
| Poor (⩾1000 blasts) | 13 (10.4) |
| BFM risk groups | |
| Standard risk | 16 (12.8) |
| Intermediate risk | 87 (69.6) |
| High risk | 22 (17.6) |
| Treatment outcome | |
| Disease relapse | |
| CCR | 106 (84.8) |
| Relapse | 19 (15.2) |
| Patients’ survival | |
| Alive | 102 (81.6) |
| Dead | 23 (18.4) |
Abbreviations: ALL=acute lymphoblastic leukaemia; B-ALL=B-lineage acute lymphoblastic leukaemia; BFM=Berlin–Frankfurt–Münster; BM=bone marrow; CCR=complete continuous remission; CD10=cluster of differentiation 10 (common acute lymphoblastic leukaemia antigen, CALLA); MRD=minimal residual disease; T-ALL=T-lineage acute lymphoblastic leukaemia; TEL-AML1=TEL-AML1 rearrangement; WBC=white blood cell.